Literature DB >> 24402426

Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.

Gunjan Sinha.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402426     DOI: 10.1093/jnci/djt447

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

Review 1.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

2.  Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.

Authors:  Hui Wang; Changqing Lu; Yan Tan; Jun Xie; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Familial breast cancer - targeted therapy in secondary and tertiary prevention.

Authors:  Karin Kast; Kerstin Rhiem
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

Review 4.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

Review 5.  Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.

Authors:  M William Audeh
Journal:  Pharmgenomics Pers Med       Date:  2014-10-03

Review 6.  Promising targets and current clinical trials in metastatic squamous cell lung cancer.

Authors:  Mark D Vincent
Journal:  Front Oncol       Date:  2014-12-09       Impact factor: 6.244

Review 7.  Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.

Authors:  Patrick Maier; Linda Hartmann; Frederik Wenz; Carsten Herskind
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

Review 8.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.

Authors:  Aniello Cerrato; Francesco Morra; Angela Celetti
Journal:  J Exp Clin Cancer Res       Date:  2016-11-24

Review 9.  Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.

Authors:  Zhengqiang Bao; Chao Cao; Xinwei Geng; Baoping Tian; Yanping Wu; Chao Zhang; Zhihua Chen; Wen Li; Huahao Shen; Songmin Ying
Journal:  Oncotarget       Date:  2016-02-16

Review 10.  PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Authors:  Geraldine O'Sullivan Coyne; Alice P Chen; Robert Meehan; James H Doroshow
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.